Cell and gene therapy developers must build continuity of engagement to create trust in the modalities, according to a report ...
Three oral and 3 poster presentations demonstrate progress of AskBio’s gene therapy research, development, and manufacturing ...
BERLIN--(BUSINESS WIRE)-- Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III ...
The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse ...
Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a ...
Bayer faces stark contrast at AGM: positive Phase III kidney drug data and gene therapy advances vs €3.6B net loss, €2.5B ...
Over the decades, Germany’s Bayer has played as big a part as any company in the discovery and development of innovative ...
Cell and gene therapies are currently niche products, even within specialty pharmacy, drugs that, by most definitions, are ...
First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results